Immune checkpoint inhibitors (ICIs), including anti-programmed cell death 1 (PD-1)/PD-L1 antibodies, have been developed as a first-line chemotherapy in metastatic GC patients with tumors with a PD-L1 CPS of ≥ 140. Here, PDCD1 is linked to gastric cancer.